Bavar­i­an Nordic gath­ers pa­tients for PhI­II RSV tri­al; Adap­ti­m­mune hand­ed $37M+ as GSK part­ner­ship ends

Dan­ish drug­mak­er Bavar­i­an Nordic grabbed head­lines last year for its pro­duc­tion of a vac­cine to treat the spread of mpox, and now it is turn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA